Irwin Hollander

3.0k citations

46 papers · 2.4k indexed · h-index 29

Organic Chemistry top 2%
- Quinazolinone synthesis and applications 6
- Synthesis and biological activity 4
Molecular Biology top 5%
- PI3K/AKT/mTOR signaling in cancer 26
- Protein Kinase Regulation and GTPase Signaling 8
Oncology top 5%
Pathology and Forensic Medicine top 5%
Genetics top 5%
- Chronic Lymphocytic Leukemia Research 6
Cancer Research
- Synthesis and Biological Activity 6
Ecology, Evolution, Behavior and Systematics
- Fungal Plant Pathogen Control 4
Spectroscopy
- Mass Spectrometry Techniques and Applications 4

Co-authors: Robert Mallon Ker Yu Semiramis Ayral‐Kaloustian Larry Feldberg Judy Lucas Philip R. Hamann Natasja Brooijmans Lourdes Toral‐Barza
Cited by: Organic Chemistry Molecular Biology Oncology
Journals: Bioorganic & Medicinal Chemistry Letters (13 papers)Journal of Medicinal Chemistry (9 papers)Analytical Chemistry (3 papers)
Partner nations: United States Canada Netherlands

In The Last Decade

Irwin Hollander

45 papers receiving 2.3k citations

Peers

Countries citing papers authored by Irwin Hollander

Since Specialization

Citations

This map shows the geographic impact of Irwin Hollander's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Irwin Hollander with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Irwin Hollander more than expected).

Fields of papers citing papers by Irwin Hollander

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Irwin Hollander. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Irwin Hollander. The network helps show where Irwin Hollander may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Irwin Hollander, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Irwin Hollander Line = papers co-authored together Irwin Hollander links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor Clinical Cancer Research ·Robert Mallon,Larry Feldberg,Judy Lucas,Indrasish Ray Chaudhuri,Christoph M. Dehnhardt,Efren Delos Santos,Zecheng Chen,Osvaldo dos Santos,Semiramis Ayral‐Kaloustian,Aranapakam M. Venkatesan,Irwin Hollander	2011	145
2	Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors Bioorganic & Medicinal Chemistry Letters ·Christoph M. Dehnhardt,Aranapakam M. Venkatesan,Zecheng Chen,Lovel Tw,Semiramis Ayral‐Kaloustian,Natasja Brooijmans,Ker Yu,Irwin Hollander,Larry Feldberg,Judy Lucas,Robert Mallon	2011	30
3	Antitumor Efficacy Profile of PKI-402, a Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor Molecular Cancer Therapeutics ·Robert Mallon,Irwin Hollander,Larry Feldberg,Judy Lucas,Veronica Soloveva,Aranapakam M. Venkatesan,Christoph M. Dehnhardt,Efren Delos Santos,Zecheng Chen,Osvaldo dos Santos,Semiramis Ayral‐Kaloustian,Jay Gibbons	2010	52
4	4-Substituted-7-azaindoles bearing a ureidobenzofuranone moiety as potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR) Bioorganic & Medicinal Chemistry Letters ·Hwei‐Ru Tsou,Jared Ray McCoppin,Gary H. Birnberg,Nan Zhang,Natasja Brooijmans,Lourdes Toral‐Barza,Irwin Hollander,Semiramis Ayral‐Kaloustian,Ker Yu	2010	19
5	Pyrazolopyrimidines as highly potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): Optimization of the 1-substituent Bioorganic & Medicinal Chemistry Letters ·Kevin J. Curran,Jeroen C. Verheijen,Joshua A. Kaplan,David J. Richard,Lourdes Toral‐Barza,Irwin Hollander,Judy Lucas,Semiramis Ayral‐Kaloustian,Ker Yu,Arie Zask	2010	61
6	Novel benzofuran-3-one indole inhibitors of PI3 kinase-α and the mammalian target of rapamycin: Hit to lead studies Bioorganic & Medicinal Chemistry Letters ·Matthew G. Bursavich,Natasja Brooijmans,王怀禹,Irwin Hollander,Stephen Kim,Sabrina Lombardi,Kaapjoo Park,Robert Mallon,A. Gilbert	2010	26
7	PKI-179: An orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor Bioorganic & Medicinal Chemistry Letters ·Aranapakam M. Venkatesan,Zecheng Chen,Osvaldo dos Santos,Christoph M. Dehnhardt,Efren Delos Santos,Semiramis Ayral‐Kaloustian,Robert Mallon,Irwin Hollander,Larry Feldberg,Judy Lucas,Ker Yu,Indrasish Ray Chaudhuri,Tarek S. Mansour	2010	59
8	Discovery of 2-ureidophenyltriazines bearing bridged morpholines as potent and selective ATP-competitive mTOR inhibitors Bioorganic & Medicinal Chemistry Letters ·Arie Zask,Jeroen C. Verheijen,David J. Richard,Joshua A. Kaplan,Kevin J. Curran,Lourdes Toral‐Barza,Judy Lucas,Irwin Hollander,Ker Yu	2010	33
9	Discovery of 2-arylthieno[3,2-d]pyrimidines containing 8-oxa-3-azabi-cyclo[3.2.1]octane in the 4-position as potent inhibitors of mTOR with selectivity over PI3K Bioorganic & Medicinal Chemistry Letters ·Jeroen C. Verheijen,Ker Yu,Lourdes Toral‐Barza,Irwin Hollander,Arie Zask	2009	32
10	Incorporation of water-solubilizing groups in pyrazolopyrimidine mTOR inhibitors: Discovery of highly potent and selective analogs with improved human microsomal stability Bioorganic & Medicinal Chemistry Letters ·David J. Richard,Jeroen C. Verheijen,Kevin J. Curran,Joshua A. Kaplan,Lourdes Toral‐Barza,Irwin Hollander,Judy Lucas,Ker Yu,Arie Zask	2009	42
11	Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-α: Hit to lead studies Bioorganic & Medicinal Chemistry Letters ·A. Gilbert,Paweł Nowak,Natasja Brooijmans,Matthew G. Bursavich,Christoph M. Dehnhardt,Efren Delos Santos,Larry Feldberg,Irwin Hollander,Stephen Kim,Sabrina Lombardi,Kaapjoo Park,Aranapakam M. Venkatesan,Robert Mallon	2009	32
12	Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors Bioorganic & Medicinal Chemistry Letters ·Aranapakam M. Venkatesan,Christoph M. Dehnhardt,Zecheng Chen,Efren Delos Santos,Osvaldo dos Santos,Matthew G. Bursavich,A. Gilbert,John W. Ellingboe,Semiramis Ayral‐Kaloustian,Gulnaz Khafizova,Natasja Brooijmans,Robert Mallon,Irwin Hollander,Larry Feldberg,Judy Lucas,Ker Yu,Jay Gibbons,Robert T. Abraham,Tarek S. Mansour	2009	23
13	Discovery of 3,6-dihydro-2H-pyran as a morpholine replacement in 6-aryl-1H-pyrazolo[3,4-d]pyrimidines and 2-arylthieno[3,2-d]pyrimidines: ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR) Bioorganic & Medicinal Chemistry Letters ·Joshua A. Kaplan,Jeroen C. Verheijen,Natasja Brooijmans,Lourdes Toral‐Barza,Irwin Hollander,Ker Yu,Arie Zask	2009	41
14	Liphagal, a new meroterpenoid from the Caribbean sponge Aka coralliphaga that shows potent and selective inhibition of P13 kinase alpha. Clinical Cancer Research ·Irwin Hollander,Frédéric Marion,David E. Williams,Robert Mallon,懐子十河,Deborah M. Roll,Larry Feldberg,R.W.M. van Soest,Raymond J. Andersen	2006	0
15	Human Ras converting enzyme endoproteolytic specificity at the P2′ and P3′ positions of K-Ras-derived peptides Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics ·Irwin Hollander,Zhangjie Li,Ann Aulabaugh,Robert Mallon	2003	7
16	An Enzyme-Linked Immunosorbent Assay for the Raf/MEK1/MAPK Signaling Cascade Analytical Biochemistry ·Robert Mallon,Larry Feldberg,Steven C. Kim,Karen Collins,Donald Wojciechowicz,Irwin Hollander,Sydney Tomholt,Constance Kohler	2001	23
17	Human Ras-Converting Enzyme (hRCE1) Endoproteolytic Activity on K-Ras-Derived Peptides Analytical Biochemistry ·Irwin Hollander,Zhangjie Li,Robert Mallon	2000	29
18	Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with In Vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785) Biochemical Pharmacology ·Carolyn Discafani,Marion L. Carroll,M. Brawner Floyd,Irwin Hollander,Zaheed Husain,Bernard D. Johnson,Douglas B. Kitchen,A A Vlasov,Madhu S. Malo,Albert A. Minnick,Ramaswamy Nilakantan,Ru Shen,Ludmila Profumo-Aguiar,Allan Wissner,Lee M. Greenberger	1999	84
19	Adenomyoepithelioma of the Breast The American Journal of Surgical Pathology ·Jeffrey H. Loose,Arthur S. Patchefsky,Irwin Hollander,Honorio Cruz-López,Harry S. Cooper,Sheila Moriber Katz	1992	123
20	Matrix-assisted UV-laser desorption/ionization mass spectrometric analysis of monoclonal antibodies for the determination of carbohydrate, conjugated chelator, and conjugated drug content Analytical Chemistry ·Marshall M. Siegel,Irwin Hollander,Philip R. Hamann,고경환,Lois M. Hinman,Bryan John Smith,S-N Zhang,厚生省大臣官房統計情報部管理企画課,David J. King,et al	1991	65

About Irwin Hollander

Irwin Hollander is a scholar working on Organic Chemistry, Genetics, Cancer Research, Molecular Biology and Biotechnology, having authored 46 papers that have together received 2.4k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (26 papers), Protein Kinase Regulation and GTPase Signaling (8 papers), Chronic Lymphocytic Leukemia Research (6 papers), Quinazolinone synthesis and applications (6 papers), Synthesis and Biological Activity (6 papers), Fungal Plant Pathogen Control (4 papers), Synthesis and biological activity (4 papers) and Mass Spectrometry Techniques and Applications (4 papers). The work is most often cited by research in Organic Chemistry (851 citations), Molecular Biology (1.3k citations), Oncology (501 citations), Pathology and Forensic Medicine (284 citations) and Genetics (167 citations). Irwin Hollander has collaborated with scholars based in United States, Canada and Netherlands. Frequent co-authors include Robert Mallon, Ker Yu, Semiramis Ayral‐Kaloustian, Larry Feldberg, Judy Lucas, Philip R. Hamann, Natasja Brooijmans, Lourdes Toral‐Barza, Aranapakam M. Venkatesan and Arie Zask. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Journal of Medicinal Chemistry, Analytical Chemistry, Molecular Cancer Therapeutics and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact